Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 7/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | PKM | P14618 | 2/20 | 0.65 |
| ▸ | HTT | P42858 | 5/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.61 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.61 |
| ▸ | ILK | Q13418 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22230114 | 0.83 | ILK (0.54) | LMNAALDH1A1PKMHTTSMN1; SMN2 | |
| SCHEMBL12799099 | 0.82 | ALDH1A1 (0.59) | LMNAALDH1A1PKMHTTSMN1; SMN2 | |
| SCHEMBL14445782 | 0.81 | LMNA (0.73) | LMNAALDH1A1PKMHTTSMN1; SMN2 | |
| SCHEMBL13678983 | 0.81 | TPSAB1 (0.61) | LMNAALDH1A1PKMHTTSMN1; SMN2 | |
| SCHEMBL609522 | 0.81 | LMNA (0.57) | LMNAALDH1A1PKMHTTSMN1; SMN2 | |
| SCHEMBL83871 | 0.81 | LMNA (0.57) | LMNAALDH1A1PKMHTTSMN1; SMN2 | |
| SCHEMBL10303833 | 0.81 | PKM (0.66) | LMNAALDH1A1PKMHTTSMN1; SMN2 | |
| SCHEMBL14514924 | 0.80 | LMNA (0.57) | LMNAALDH1A1PKMHTTSMN1; SMN2 | |
| SCHEMBL10303844 | 0.80 | ILK (0.62) | LMNAALDH1A1PKMHTTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL28774873 | 0.79 | LMNA (0.56) | LMNAALDH1A1PKMHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2455431-B1 | Ink and ink set for inkjet recording | FUJIFILM CORP (JP) | 2013-08-21 | — | — | EP | disclosed |
| US-20120165309-A1 | HETERO RING DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-28 | — | — | US | disclosed |
| EP-2397479-A1 | HETERO RING DERIVATIVE | Astellas Pharma Inc. (JP) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010092962-A1 | HETERO RING DERIVATIVE | アステラス製薬株式会社 (JP) | 2010-08-19 | — | — | WO | disclosed |
| US-20090043081-A1 | INK JET RECORDING SET AND INK JET RECORDING METHOD | FUJIFILM CORPORATION (JP) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165309-A1 | HETERO RING DERIVATIVE | IL2, PIK3R2, IL2RA | LMNA 4381/4885ALDH1A1 3496/4885PKM 4499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.